Orphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"

The US FDA will present its verdict on Orphazyme's drug candidate arimoclomol for treating NPC on June 17 at latest. According to an analyst and a former investor, the outcome is crucial to the Danish biotech firm.

Photo: Orphazyme/PR

Orphazyme's fate as a biotech company may be at stake when the US Food and Drug Administration (FDA) decides whether arimoclomol can be approved as a treatment for the rare metabolic disorder Niemann-Pick type C (NPC), says Danske Market's Senior Analyst Thomas Bowers.

"Clearly, its existence will be threatened if it gets a clear no and arimoclomol never gets to be an NPC product in the US," the analyst tells MedWatch.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs